{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:08:47Z","timestamp":1791576527818,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We identified 71 patients with AdvSM (aggressive SM [ASM], SM with an associated hematologic neoplasm [SM-AHN, e.g., acute myeloid leukemia, SM-AML], mast cell leukemia [MCL]) in two national registries (DRST\/GREM) who received an allogeneic hematopoietic cell transplantation (alloHCT) performed in Germany from 1999\u20132021. Median overall survival (OS) of ASM\/SM-AHN (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200930, 45%), SM-AML (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200928, 39%) and MCL\u2009\u00b1\u2009AHN (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200913, 19%) was 9.0, 3.3 and 0.9 years (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.007). Improved median OS was associated with response of SM (17\/41, 41%; HR 0.4 [0.2\u20130.9],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.035) and\/or of AHN (26\/43, 60%, HR 0.3 [0.1\u20130.7],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.004) prior to alloHCT. Adverse predictors for OS included absence of\n                    <jats:italic>KIT<\/jats:italic>\n                    D816V (10\/61, 16%, HR 2.9 [1.2\u20136.5],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and a complex karyotype (9\/60, 15%, HR 4.2 [1.8\u201310.0],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.016). HLA-match, conditioning type or transplantation at centers reporting above-average alloHCTs (\u22657) had no impact on OS. Taking into account competing events at years 1, 3 and 5, relapse-related mortality and non-relapse mortality rate were 15%\/23%, 20%\/30% and 23%\/35%, respectively. Irrespective of subtype, subsequent treatment response was achieved in 13\/30 (43%) patients and was highest on midostaurin\/avapritinib (7\/9, 78%). We conclude that outcome of alloHCT in AdvSM is more affected by disease phenotype and treatment response prior to transplant than by transplant characteristics.\n                  <\/jats:p>","DOI":"10.1038\/s41375-024-02186-x","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T12:02:17Z","timestamp":1709726537000},"page":"810-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-1504","authenticated-orcid":false,"given":"Johannes","family":"L\u00fcbke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Christen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Shoumariyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-0804","authenticated-orcid":false,"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-7299","authenticated-orcid":false,"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Schaffrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kaivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4853-5579","authenticated-orcid":false,"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wittke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hertenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Radsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeska","family":"Br\u00fcckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-6507","authenticated-orcid":false,"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6316-3112","authenticated-orcid":false,"given":"Jens","family":"Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"2186_CR1","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5:e646.","journal-title":"Hemasphere"},{"key":"2186_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603\u201325.","journal-title":"Leuk Res"},{"key":"2186_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2186_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2186_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","volume":"93","author":"P Erben","year":"2014","unstructured":"Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol. 2014;93:81\u20138.","journal-title":"Ann Hematol"},{"key":"2186_CR6","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.3390\/ijms22052562","volume":"22","author":"N Naumann","year":"2021","unstructured":"Naumann N, L\u00fcbke J, Baumann S, Schwaab J, Hoffmann O, Kreil S, et al. Adverse prognostic impact of the KIT D816V transcriptional activity in advanced systemic mastocytosis. Int J Mol Sci. 2021;22:2562.","journal-title":"Int J Mol Sci"},{"key":"2186_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","volume":"29","author":"M Arock","year":"2015","unstructured":"Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29:1223\u201332.","journal-title":"Leukemia"},{"key":"2186_CR8","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.19.00640","volume":"37","author":"M Jawhar","year":"2019","unstructured":"Jawhar M, Schwaab J, Alvarez-Twose I, Shoumariyeh K, Naumann N, L\u00fcbke J, et al. MARS: mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol. 2019;37:2846\u201356.","journal-title":"J Clin Oncol"},{"key":"2186_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","volume":"130","author":"M Jawhar","year":"2017","unstructured":"Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130:137\u201345.","journal-title":"Blood"},{"key":"2186_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, et al. Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia. 2016;30:136\u201343.","journal-title":"Leukemia"},{"key":"2186_CR11","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/leu.2016.190","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, et al. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia. 2016;30:2342\u201350.","journal-title":"Leukemia"},{"key":"2186_CR12","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460\u20136.","journal-title":"Blood"},{"key":"2186_CR13","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00277-023-05180-y","volume":"102","author":"J L\u00fcbke","year":"2023","unstructured":"L\u00fcbke J, Naumann N, Metzgeroth G, Kreil S, Brand T, Horny HP, et al. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis. Ann Hematol. 2023;102:2077\u201385.","journal-title":"Ann Hematol"},{"key":"2186_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/bjh.17932","volume":"196","author":"A Tefferi","year":"2022","unstructured":"Tefferi A, Kittur J, Farrukh F, Begna KH, Patnaik MM, Al-Kali A, et al. Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. Br J Haematol. 2022;196:975\u201383.","journal-title":"Br J Haematol"},{"key":"2186_CR15","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van \u2018t Wout JW, Verhoef G, Gerrits WB, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270\u20136.","journal-title":"Blood"},{"key":"2186_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","volume":"126","author":"S Barete","year":"2015","unstructured":"Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126:1009\u201316.","journal-title":"Blood"},{"key":"2186_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ajh.26498","volume":"97","author":"A Singh","year":"2022","unstructured":"Singh A, Al-Kali A, Begna KH, Litzow MR, Larsen JT, Sher T, et al. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. Am J Hematol. 2022;97:630\u20137.","journal-title":"Am J Hematol"},{"key":"2186_CR18","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1200\/JCO.21.01849","volume":"40","author":"J L\u00fcbke","year":"2022","unstructured":"L\u00fcbke J, Schwaab J, Naumann N, Horny HP, Wei\u00df C, Metzgeroth G, et al. Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis. J Clin Oncol. 2022;40:1783\u201394.","journal-title":"J Clin Oncol"},{"key":"2186_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/leu.2017.234","volume":"32","author":"DJ DeAngelo","year":"2018","unstructured":"DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32:470\u20138.","journal-title":"Leukemia"},{"key":"2186_CR20","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N. Engl J Med. 2016;374:2530\u201341.","journal-title":"N. Engl J Med"},{"key":"2186_CR21","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1056\/NEJMc1515403","volume":"374","author":"MO Chandesris","year":"2016","unstructured":"Chandesris MO, Damaj G, Canioni D, Brouzes C, Lhermitte L, Hanssens K, et al. Midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2605\u20137.","journal-title":"N Engl J Med"},{"key":"2186_CR22","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","volume":"36","author":"A Reiter","year":"2022","unstructured":"Reiter A, Gotlib J, \u00c1lvarez-Twose I, Radia DH, L\u00fcbke J, Bobbili PJ, et al. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia. 2022;36:2108\u201320.","journal-title":"Leukemia"},{"key":"2186_CR23","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1182\/bloodadvances.2022007539","volume":"6","author":"A Reiter","year":"2022","unstructured":"Reiter A, Schwaab J, DeAngelo DJ, Gotlib J, Deininger MW, Pettit KM, et al. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Adv. 2022;6:5750\u201362.","journal-title":"Blood Adv"},{"key":"2186_CR24","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27:2183\u201391.","journal-title":"Nat Med"},{"key":"2186_CR25","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","volume":"27","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27:2192\u20139.","journal-title":"Nat Med"},{"key":"2186_CR26","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","volume":"32","author":"C Ustun","year":"2014","unstructured":"Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32:3264\u201374.","journal-title":"J Clin Oncol"},{"key":"2186_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.V91.3.756","volume":"91","author":"S Slavin","year":"1998","unstructured":"Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756\u201363.","journal-title":"Blood"},{"key":"2186_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","volume":"39","author":"L Luznik","year":"2012","unstructured":"Luznik L, O\u2019Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683\u201393.","journal-title":"Semin Oncol"},{"key":"2186_CR29","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","volume":"6","author":"R Shouval","year":"2019","unstructured":"Shouval R, Fein JA, Labopin M, Kr\u00f6ger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573\u201384.","journal-title":"Lancet Haematol"},{"key":"2186_CR30","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2186_CR31","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","volume":"121","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013;121:2393\u2013401.","journal-title":"Blood"},{"key":"2186_CR32","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.jaip.2022.05.034","volume":"10","author":"J Gotlib","year":"2022","unstructured":"Gotlib J, Schwaab J, Shomali W, George TI, Radia DH, Castells M, et al. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis. J Allergy Clin Immunol Pr. 2022;10:2025\u201338.e1.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"2186_CR33","doi-asserted-by":"crossref","unstructured":"Shomali W, Gotlib J. Response criteria in advanced systemic mastocytosis: evolution in the Era of KIT inhibitors. Int J Mol Sci. 2021;22:2983.","DOI":"10.3390\/ijms22062983"},{"key":"2186_CR34","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1182\/blood.V128.22.945.945","volume":"128","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Naumann N, Kluger S, Horny H-P, Sotlar K, et al. Impact of molecular markers on response and resistance in midostaurin-treated patients with advanced systemic mastocytosis. Blood. 2016;128:945.","journal-title":"Blood"},{"key":"2186_CR35","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41375-019-0450-8","volume":"33","author":"J L\u00fcbke","year":"2019","unstructured":"L\u00fcbke J, Naumann N, Kluger S, Schwaab J, Metzgeroth G, Evans E, et al. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Leukemia. 2019;33:1195\u2013205.","journal-title":"Leukemia"},{"key":"2186_CR36","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865\u201373.","journal-title":"Haematologica"},{"key":"2186_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2014.9","volume":"49","author":"C Anthias","year":"2014","unstructured":"Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transpl. 2014;49:679\u201383.","journal-title":"Bone Marrow Transpl"},{"key":"2186_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/leu.2014.173","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29:137\u201344.","journal-title":"Leukemia"},{"key":"2186_CR39","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.V99.6.2002","volume":"99","author":"AE Woolfrey","year":"2002","unstructured":"Woolfrey AE, Anasetti C, Storer B, Doney K, Milner LA, Sievers EL, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood. 2002;99:2002\u20138.","journal-title":"Blood"},{"key":"2186_CR40","doi-asserted-by":"publisher","first-page":"103398","DOI":"10.1016\/j.retram.2023.103398","volume":"71","author":"P Sriskandarajah","year":"2023","unstructured":"Sriskandarajah P, McLornan DP, Oni C, Wilson AJ, Woodley C, Ciesielska M, et al. Advanced systemic mastocytosis with associated haematological neoplasm: treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant. Curr Res Transl Med. 2023;71:103398.","journal-title":"Curr Res Transl Med"},{"key":"2186_CR41","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T de Witte","year":"2017","unstructured":"de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753\u201362.","journal-title":"Blood"},{"key":"2186_CR42","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.bbmt.2019.03.022","volume":"25","author":"M Jentzsch","year":"2019","unstructured":"Jentzsch M, Geus U, Grimm J, Vucinic V, P\u00f6nisch W, Franke GN, et al. Pretreatment CD34(+)\/CD38(-) cell burden as prognostic factor in myelodysplastic syndrome patients receiving allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:1560\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2186_CR43","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","volume":"22","author":"C Ustun","year":"2016","unstructured":"Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transpl. 2016;22:1348\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2186_CR44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","volume":"124","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344\u201353.","journal-title":"Blood"},{"key":"2186_CR45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","volume":"116","author":"F Kreidieh","year":"2022","unstructured":"Kreidieh F, Abou Dalle I, Moukalled N, El-Cheikh J, Brissot E, Mohty M, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Int J Hematol. 2022;116:330\u201340.","journal-title":"Int J Hematol"},{"key":"2186_CR46","doi-asserted-by":"crossref","unstructured":"Schwaab J, Cabral do OHN, Naumann N, Jawhar M, Wei\u00df C, Metzgeroth G, et al. Importance of adequate diagnostic work-up for correct diagnosis of advanced systemic mastocytosis. J Allergy Clin Immunol Pract. 2020;8:3121\u201327.","DOI":"10.1016\/j.jaip.2020.05.005"},{"key":"2186_CR47","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/eci.12607","volume":"46","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Horny HP, Sotlar K, Naumann N, Fabarius A, et al. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Invest. 2016;46:392\u20137.","journal-title":"Eur J Clin Invest"},{"key":"2186_CR48","unstructured":"DeAngelo DJ, Quiery AT, Radia D, Drummond MW, Gotlib JR, WA, Hexner E, et al. Clinical activity in a Phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis. American Society of Hematology Annual Meeting, Atlanta. 2017."},{"key":"2186_CR49","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/ajh.24880","volume":"92","author":"J Gotlib","year":"2017","unstructured":"Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:1243\u201359.","journal-title":"Am J Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02186-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02186-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02186-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T11:04:34Z","timestamp":1712315074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02186-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2186"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02186-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"23 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DC received consulting fees from Blueprint Medicines, Novartis, Pfizer and BeiGene, honoraria from Blueprint Medicines, Novartis and AstraZeneca and travel support from Amgen and Janssen. JS received consulting fees from Blueprint Medicines and GlaxoSmithKline, honoraria from Blueprint Medicines, GlaxoSmithKline and Novartis and research funding from GlaxoSmithKline. KS received consulting fees from Blueprint Medicines, honoraria from Astra Zeneca and Novartis and participated in the speakers bureau of BMS. MJ received consulting fees from Novartis and honoraria from Amgen, Blueprint Medicines, BMS, Jazz Pharmaceuticals, Novartis and Pfizer. KS received consulting fees and honoraria from Blueprint Medicines, BMS and Novartis, lecture fees from GlaxoSmithKline and research support from Active Biotech. IK received consulting fees from Novartis, honoraria from AbbVie, Medac, Novartis and Takeda and travel support from Medac, Amgen, BeiGene, Jazz Pharmaceuticals, Janssen and Fondation Internationale Menarini. ES received consulting fees from Jazz Pharmaceuticals, BMS, Kite Gilead and Takeda, honoraria from Jazz Pharmaceuticals, BMS, Kite Gilead and Novartis and support for meeting attendance from Jazz Pharmaceuticals and Kite Gilead. SS received honoraria from Prothena, Janssen, Takeda and Pfizer, research funding from Prothena, Janssen and Sanofi and travel support from Prothena, Janssen, Celgene, Binding Site and Jazz Pharmaceuticals. MR received honoraria from BMS, Novartis, Takeda, Incyte, Corat, Cogent Biosciences, TEVA, Otsuka, Lilly, Abbvie, Pfizer, Beigene and GlaxoSmithKline, research funding from Novartis and travel support from BMS, Novartis, Abbvie, Jazz Pharmaceuticals, Daiichi Sankyo, Amgen, Astellas, SOBI and AOP. THB received consulting fees from Gilead, Janssen, Merck, Novartis and Pfizer, honoraria from Janssen, Merck and Novartis, research funding from Novartis and Pfizer, participated in the speakers bureaus of Gilead, Janssen, Merck, Novartis and Pfizer and was paid for patents and royalties from Novartis. SK received honoraria from Amgen. EJ received honoraria from BMS, Jazz Pharmaceuticals and Amgen and travel support from Medac. AR received consulting fees, honoraria and research funding from Abbvie, AOP Orphan Pharmaceuticals, Blueprint Medicines Corporation, BMS, GlaxoSmithKline, Incyte and Novartis and was member on an entity\u2019s Board of Directors or advisory committees of Abbvie, AOP Orphan Pharmaceuticals, Blueprint Medicines, BMS, GSK, Incyte and Novartis. JP received consulting fees from Amgen, Apellis Pharmaceuticals, BMS, MSD and Sanofi and was member on an entity\u2019s Board of Directors or advisory committees and Speakers Bureau of Alexion, AstraZeneca Rare Disease, Boehring Ingelheim, Blueprint Medicines, Novartis, Pfizer, Samsung Bioepis, SOBI and F. Hoffmann-La Roche Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}